65,437 trials
Prostate Cancer
Primary: Progression Free Survival — 1.83; 3.7 months
Spinal Fractures · Osteoporosis
Primary: Back-specific Functional Status Using Roland-Morris Disability Questionnaire (RDQ) Scale at 1 Month — 12.0; 13.0 units on a scale — p=0.49
Foot Ulcer, Diabetic · Diabetic Foot
Primary: The Primary Efficacy Parameter Will be the Proportion of Ulcers Healed by 12 Weeks as Defined as 100 % Epithelialized With no Drainage. — 8; 14; 8 number of ulcers healed
Asthma
Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. — 0.315; 0.401 Liter — p=0.0110
Tuberculosis
Primary: Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18…
Irritable Bowel Syndrome With Diarrhea
Primary: The Number of Months That Subjects Are Monthly Responders in Both IBS-related Abdominal Pain AND Stool Consistency During the Entire Three Months. — 18; 27; 28; 9…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c After 24 Weeks — 0.07; -0.58 Percentage — p=<0.0001
Fatty Liver
Primary: Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L — 9; 15; 10 participants — p=0.26
Mucosal Melanoma · Recurrent Melanoma · Stage IIIA Skin Melanoma
Primary: Overall Survival — 11.1; 11.3 months — p=0.863
Breakthrough Pain · Cancer
Primary: Dose of Instanyl — 75; 30; 50; 69 participants
Idiopathic Restless Legs Syndrome
Primary: Restless Legs Syndrome (RLS) Symptom Severity — 22.30; 22.40; 22.10; 22.40 Units on a Scale
Glioblastoma Multiforme · Gliosarcoma
Primary: Overall Survival — 19 months
Urinary Incontinence
Primary: Objective Treatment Success at 12 Months — 80.8; 77.7 percentage of participants
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Rheumatoid Arthritis
Primary: ACR20 Responses at Week 24 — 11; 54 participants